Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Cited by (1,004)

Items 301–400 of 1,004

1. Engineering the next generation of CAR-NK immunotherapies
   Alexander Biederstädt, Katayoun Rezvani · 2021 · International Journal of Hematology
2. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion
   Michael Olson, Erica R. Vander Mause, Sabarinath Venniyil Radhakrishnan, Joshua Brody, Aaron P. Rapoport, Alana L. Welm, Djordje Atanackovic, Tim Luetkens · 2022 · Leukemia
3. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date.
   Stephanie Si, David T. Teachey · 2020 · PubMed Central
4. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
   Nadia El Khawanky, Amy Hughes, Wenbo Yu, Renier Myburgh, Tony Matschulla, Sanaz Taromi, Konrad Aumann, Jade Clarson, Janaki Manoja Vinnakota, Khalid Shoumariyeh et al. · 2021 · Nature Communications
5. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia
   Caitlin C. Zebley, Charmaine Brown, Mi Tian, Yiping Fan, Shanta Alli, Shannon Kathryn Boi, Giovanni Galletti, Enrico Lugli, Deanna M. Langfitt, Jean‐Yves Métais et al. · 2021 · Cell Reports
6. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
   Ankit J. Kansagra, Noelle V. Frey, Merav Bar, Theodore Willis Laetsch, Paul A. Carpenter, Bipin N. Savani, Helen Elisabeth Heslop, Catherine M. Bollard, Krishna V. Komanduri, Dennis A. Gastineau et al. · 2018 · Transplantation and Cellular Therapy
7. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
   Hong Qin, Zhenyuan Dong, Xiuli Wang, Wesley A. Cheng, Feng Wen, Weili Xue, Han Sun, Miriam Walter, Guo‐Wei Wei, Diane Lynne Smith et al. · 2019 · Science Translational Medicine
8. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
   Victoria Gutgarts, Tania Jain, Junting Zheng, Molly Maloy, Josel D. Ruiz, Martina Pennisi, Edgar A. Jaimes, Miguel‐Angel Perales, Jaffer Sathick · 2020 · Transplantation and Cellular Therapy
9. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
   Hardikkumar Jetani, Almudena Navarro‐Bailón, Marius Maucher, Silke Frenz, Christina Verbruggen, Ana Yeguas, María‐Belén Vídriales, Marcos González, Judit Rial Saborido, Sabrina Kraus et al. · 2021 · Blood
10. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines
    Connor J. Dwyer, Hannah M. Knochelmann, Aubrey S. Smith, Megan M. Wyatt, Guillermo O. Rangel Rivera, Dimitrios C. Arhontoulis, Eric Bartee, Zihai Li, Mark P. Rubinstein, Chrystal Mary Paulos · 2019 · Frontiers in Immunology
11. CAR-T cell potency: from structural elements to vector backbone components
    Marzieh Mazinani, Fatemeh Rahbarizadeh · 2022 · Biomarker Research
12. Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice
    Rujul H Parikh, Sagar Lonial · 2023 · CA A Cancer Journal for Clinicians
13. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
    Paula Salmikangas, Niamh M. Kinsella, Paul Chamberlain · 2018 · Pharmaceutical Research
14. Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies
    Ying Wang, Kunming Qi, Hai Cheng, Jiang Cao, Ming Shi, Jianlin Qiao, Zhiling Yan, Guangjun Jing, Bin Pan, Wei Sang et al. · 2019 · Transplantation and Cellular Therapy
15. Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer
    Cassandra E. Callmann, Lisa E. Cole, Caroline D. Kusmierz, Ziyin N. Huang, Dai Horiuchi, Chad Alexander Mirkin · 2020 · Proceedings of the National Academy of Sciences
16. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
    Runxia Gu, Fang Liu, Dehui Zou, Yingxi Xu, Lu Yang, Bingcheng Liu, Wei Liu, Xiaojuan Chen, Kaiqi Liu, Ye Guo et al. · 2020 · Journal of Hematology & Oncology
17. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia
    Elias Joseph Jabbour, Ching‐Hon Pui, Hagop M. Kantarjian · 2018 · JAMA Oncology
18. Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma
    Jackson, Zachary, Roe, Anne, Sharma, Ashish Arunkumar, Lopes, Filipa Blasco Tavares Pereira, Talla, Aarthi, Kleinsorge-Block, Sarah, Zamborsky, Kayla, Schiavone, Jennifer, Manjappa, Shivaprasad, Schauner, Robert et al. · 2020 · Frontiers in Immunology
19. A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells
    Darin Bloemberg, Tina Nguyen, Susanne MacLean, Ahmed Zafer, Christine Gadoury, Komal Gurnani, Anindita Chattopadhyay, Josée Ash, Julie Lippens, Doreen Harcus et al. · 2020 · Molecular Therapy — Methods & Clinical Development
20. State of the art in CAR T cell therapy for CD19+ B cell malignancies
    Matthew J. Frigault, Marcela Valderrama Maus · 2020 · Journal of Clinical Investigation
21. Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
    Simon Loff, Josephine Dietrich, Jan-Erik Meyer, Julia Riewaldt, Johannes Spehr, Malte v. Bonin, Cordula Gründer, Mridula Swayampakula, Kristin Franke, Anja Feldmann et al. · 2020 · Molecular Therapy — Oncolytics
22. Dose–response correlation for CAR-T cells: a systematic review of clinical studies
    Anand Rotte, Matthew J. Frigault, Ayub Ansari, Brad Gliner, Christopher Ryan Heery, Bijal Dinesh Shah · 2022 · Journal for ImmunoTherapy of Cancer
23. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Mark Blaine Geyer, Isabelle Rivière, Brigitte Sénéchal, Xiuyan Wang, Yongzeng Wang, Terence J. Purdon, Meier Hsu, Sean M. Devlin, Maria Lia Palomba, Elizabeth F. Halton et al. · 2019 · JCI Insight
24. Single-Cell Analysis of CAR-T Cell Activation Reveals A Mixed T H 1/T H 2 Response Independent of Differentiation
    Iva Xhangolli, Burak Dura, GeeHee Lee, Dongjoo Kim, Yang Xiao, Rong Fan · 2019 · Genomics Proteomics & Bioinformatics
25. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
    Haneen Shalabi, Vandana Sachdev, Amita Kulshreshtha, Julia Wanda Cohen, Bonnie Yates, Doug R Rosing, Stanislav Sidenko, Cindy Delbrook, Crystal Lee Mackall, Brandon M. Wiley et al. · 2020 · Journal for ImmunoTherapy of Cancer
26. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
    Matthias Totzeck, Lars Michel, Yi Lin, Joerg Herrmann, Tienush Rassaf · 2022 · European Heart Journal
27. Development of CAR-T cell therapies for multiple myeloma
    Nico Gagelmann, Kristoffer Riecken, Christine Wolschke, Carolina Berger, Francis Ayuketang Ayuk, Boris Fehse, Nicolaus Kröger · 2020 · Leukemia
28. Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives
    Yang Shi · 2020 · Advanced Therapeutics
29. The EBMT/EHA CAR-T Cell Handbook
    Nicolaus Kröger, John G. Gribben, Christian Chabannon, Ibrahim Yakoub‐Agha, Hermann Einsele · 2022 · Springer eBooks
30. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
    Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, Samantha M. Y. Chen, Zhangguo Chen, Jing Hong Wang · 2020 · Protein & Cell
31. Neurological updates: neurological complications of CAR-T therapy
    Emma Clare Tallantyre, Nia A. Evans, Jack Parry-Jones, Matt P. G. Morgan, Ceri H. Jones, Wendy A Ingram · 2020 · Journal of Neurology
32. T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
    Palak H. Mehta, Salvatore Fiorenza, Rachel M. Koldej, Anthony Jaworowski, David S. Ritchie, Kylie M. Quinn · 2021 · Frontiers in Immunology
33. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?
    Sanne B. Schagen, Andrey S. Tsvetkov, Annette Compter, Jeffrey Scott Wefel · 2022 · Nature Reviews Neurology
34. Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
    Daniel Bryan Goodman, Camillia S. Azimi, Kendall Kearns, Alexis Talbot, Kiavash Garakani, Julie M. Garcia, Nisarg A. Patel, Byungjin Hwang, David S. Lee, Minhee Park et al. · 2022 · Science Translational Medicine
35. New Approaches to the Management of Adult Acute Lymphoblastic Leukemia
    Renato Bassan, Jean‐Pierre Bourquin, Daniel J. DeAngelo, Sabina Chiaretti · 2018 · Journal of Clinical Oncology
36. Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
    Alexandros Nianias, Maria Themeli · 2019 · Current Hematologic Malignancy Reports
37. CAR-T cell therapy: a potential new strategy against prostate cancer
    Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, Cecilia Menna, Amelia Altavilla, Cristian Lolli, Claudio Cerchione, Giovanni Paganelli, Daniele Santini, Giuseppe Tonini et al. · 2019 · Journal for ImmunoTherapy of Cancer
38. The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
    Niels Schaft · 2020 · Cancers
39. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia
    Weimin Kong, Alexander J. Dimitri, Wang Wenliang, In-Young Jung, Christopher J. Ott, Maria Fasolino, Yan Wang, Irina M. Kulikovskaya, Minnal Gupta, Todd Yoder et al. · 2021 · Journal of Clinical Investigation
40. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
    Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, Raymone Pajarillo, Christopher Tor Sauter, Ruchi P. Patel, Hatcher J. Ballard, Seok Jae Hong, Inkook Chun, Nicholas Yang et al. · 2022 · Cancer Discovery
41. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
    Felix Korell, Trisha R. Berger, Marcela Valderrama Maus · 2022 · Med
42. Disruption of SUV39H1 -Mediated H3K9 Methylation Sustains CAR T-cell Function
    Jain, Nayan, Zhao, Zeguo, Koche, Richard P., Antelope, Chenling, Gozlan, Yosi, Montalbano, Antonino, Brocks, David, Lopez, Michael, Dobrin, Anton, Shi, Yuzhe et al. · 2024 · Cancer Discovery
43. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
    Concetta Quintarelli, Simona Sivori, Simona Caruso, Simona Carlomagno, Michela Falco, Iolanda Boffa, Domenico Orlando, Marika Guercio, Zeinab Abbaszadeh, Matilde Sinibaldi et al. · 2019 · Leukemia
44. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
    Frank M. Cichocki, Sjoukje J. C. van der Stegen, Jeffrey S. Miller · 2022 · Blood
45. BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
    Eric L. Smith, Sham Mailankody, Mette Stæhr, Xiuyan Wang, Brigitte Sénéchal, Terence J. Purdon, Anthony F. Daniyan, Mark Blaine Geyer, Aaron D. Goldberg, Elena Mead et al. · 2019 · Cancer Immunology Research
46. Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment
    Jessica Rice, Sarah Jordan Nagle, Julie Randall, Holly E. Hinson · 2019 · Current Treatment Options in Neurology
47. Biomaterial scaffold-based local drug delivery systems for cancer immunotherapy
    Chen Yang, Nicholas Thomas Blum, Jing Lin, Junle Qu, Peng Huang · 2020 · 中国科学通报：英文版
48. Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications
    Caio Raony Farina Silveira, Amanda Cristina Corveloni, Sâmia Rigotto Caruso, Nathália Araújo Macêdo, Natália Moscheta Brussolo, Felipe Haddad, Taísa Risque Fernandes, Pamela Viani de Andrade, Maristela Delgado Orellana, Renato Cunha · 2022 · Frontiers in Immunology
49. Determinants of response and resistance to CAR T cell therapy
    Stefanie Lesch, Mohamed-Reda Benmebarek, Bruno Loureiro Cadilha, Stefan Stoiber, Marion S. Subklewe, Stefan Endres, Sebastian Kobold · 2019 · Seminars in Cancer Biology
50. Promising approaches in cancer immunotherapy
    Nima Taefehshokr, Behzad Baradaran, Amir Baghbanzadeh, Sina Taefehshokr · 2019 · Immunobiology
51. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells
    Renier Myburgh, Jonathan D. Kiefer, Norman F. Russkamp, Chiara Francesca Magnani, Nicolás Gonzalo Núñez, Alexander Simonis, Surema Pfister, Christian Matthias Wilk, Donal McHugh, Juliane Friemel et al. · 2020 · Leukemia
52. Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche
    Chao Ma, Matthew T. Witkowski, Jacob Harris, Igor Dolgalev, Sheetal Sreeram, Weiyi Qian, Jie Tong, Xin Chen, Iannis Aifantis, Weiqiang Chen · 2020 · Science Advances
53. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies
    Erica T. Goddard, Miles Hamilton Linde, Shivani Srivastava, Grant Klug, Tamer Basel Shabaneh, Santino Iannone, Candice Alexandra Grzelak, Sydney A. Marsh, Alessandra I. Riggio, Ryann E. Shor et al. · 2024 · Cancer Cell
54. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy
    Cassie K. Chou, Cameron John Turtle · 2020 · Expert Opinion on Biological Therapy
55. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients
    Lihua Yu, Lulu Huang, Danna Lin, Xiaorong Lai, Li Wu, Xu Liao, Jiale Liu, Yinghua Zeng, Lichan Liang, Guanmei Zhang et al. · 2021 · Journal of Cancer Research and Clinical Oncology
56. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy
    Xia Li, Mi Shao, Xiangjun Zeng, Pengxu Qian, He Huang · 2021 · Signal Transduction and Targeted Therapy
57. Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
    Bailu Xie, Zhengdong Li, Jianfeng Zhou, Wen Wang · 2022 · Cancers
58. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions
    Ying‐Jun Chang, Xuying Pei, Xiao‐Jun Huang · 2022 · The Lancet Haematology
59. Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis
    Wenliang Yu, Zichun Hua · 2019 · Cancers
60. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma
    Edward Allen Stadtmauer, Thomas H. Faitg, Daniel E. Lowther, Ashraf Z. Badros, Karen Chagin, Karen Dengel, Malini K. Iyengar, Luca Melchiori, Jean‐Marc Navenot, Elliot Norry et al. · 2019 · Blood Advances
61. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma
    Nicola Tumino, Gerrit Weber, Francesca Besi, Francesca Del Bufalo, Valentina Bertaina, Paola Paci, Linda Quatrini, Laura Antonucci, Matilde Sinibaldi, Concetta Quintarelli et al. · 2021 · Journal of Hematology & Oncology
62. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
    Derek P. Wong, Nand Kishor Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey, Samantha K. Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber et al. · 2022 · Nature Communications
63. The next wave of cellular immunotherapies in pancreatic cancer
    Dannel Yeo, Caroline Giardina, Payal Saxena, John E.J. Rasko · 2022 · Molecular Therapy — Oncolytics
64. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
    Linde Dekker, Friso Calkoen, Yilin Jiang, Hilly Blok, Saskia R Veldkamp, Coco C. H. de Koning, Maike Spoon, Rick Admiraal, Peter M. Hoogerbrugge, Britta Julia Vormoor et al. · 2022 · Blood Advances
65. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research
    Eliza Maria Lauer, Jurik Mutter, Florian Scherer · 2022 · Leukemia
66. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
    Yaojie Kong, Jingyao Li, Xueyao Zhao, Yanwei Wu, Liang Chen · 2025 · Frontiers in Immunology
67. Posttransplant chimeric antigen receptor therapy
    Melody M. Smith, Johannes L. Zakrzewski, Scott E. James, Michel Sadelain · 2018 · Blood
68. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
    Liang Lin, Shih‐Feng Cho, Lijie Xing, Kenneth Wen, Yuyin Li, Tengteng Yu, Phillip A. Hsieh, Hailin Chen, Metin Kurtoğlu, Yi Zhang et al. · 2020 · Leukemia
69. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
    Deming Duan, Keke Wang, Wei Cheng, Dudu Feng, Yonghua Liu, Qingyan He, Xing Xu, Chunling Wang, Shuping Zhao, Leili Lv et al. · 2021 · Frontiers in Immunology
70. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments
    Lisa A. Feldman · 2024 · Frontiers in Immunology
71. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
    Matthew R. Collinson-Pautz, Wei-Chun Chang, An Lu, Mariam Khalil, Jeannette Crisostomo, Pei-Yi Lin, Aruna Mahendravada, Nicholas P. Shinners, Mary E. Brandt, Ming Zhang et al. · 2019 · Leukemia
72. Clinical development of CAR T cell therapy in China: 2020 update
    Jianshu Wei, Yelei Guo, Yao Wang, Zhiqiang Wu, Jian Bo, Bin Zhang, Jun Zhu, Weidong Han · 2020 · Cellular and Molecular Immunology
73. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells
    Young-Ho Lee, Hyeong Ji Lee, Hyung Cheol Kim, Yujean Lee, Su Kyung Nam, Cedric Hupperetz, Jennifer S. Y. Ma, Xinxin Wang, Oded Singer, Won Seog Kim et al. · 2021 · Molecular Therapy
74. Oncologic emergencies and urgencies: A comprehensive review
    Bonnie E. Gould Rothberg, Tammie E. Quest, Sai‐Ching J. Yeung, Lorraine Cheryl Pelosof, David E. Gerber, Justin A. Seltzer, Jason J. Bischof, Charles R. Thomas, Nausheen Akhter, Mira Mamtani et al. · 2022 · CA A Cancer Journal for Clinicians
75. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center
    Karlo Perica, Kevin Joseph Curran, Renier J. Brentjens, Sergio Giralt · 2018 · Transplantation and Cellular Therapy
76. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
    Jean‐François Rossi, Patrice Céballos, ZY Lu · 2019 · 癌症：英文版
77. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
    Lorenzo Lindo, Lauren Wilkinson, Kevin Anthony Hay · 2021 · Frontiers in Immunology
78. YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies
    Zhenhua Chen, Chengwu Zeng, Lu Yang, Yuan Che, Meiling Chen, Lillian Sau, Bintao Wang, Keren Zhou, Yu Chen, Ying Qing et al. · 2024 · Cell
79. Updates on CAR T‐cell therapy in B‐cell malignancies
    Elad Jacoby, Shilpa A. Shahani, Nirali N. Shah · 2019 · Immunological Reviews
80. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
    Houli Zhao, Jieping Wei, Guoqing Wei, Yi Luo, Jimin Shi, Qu Cui, Mingfeng Zhao, Aibin Liang, Qing Zhang, Jianmin Yang et al. · 2020 · Journal of Hematology & Oncology
81. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
    Hanna Meister, Thomas Look, Patrick Roth, Steve Pascolo, Uğur Şahin, Sohyon Lee, Benjamin D. Hale, Berend Snijder, Luca Regli, Vidhya Madapusi Ravi et al. · 2022 · Clinical Cancer Research
82. Cellular immunotherapies for cancer
    Conall Hayes · 2020 · Irish Journal of Medical Science (1971 -)
83. Acute Lymphoblastic Leukemia in the Older Adult
    Ibrahim Taha Aldoss, Stephen J. Forman, Vinod A. Pullarkat · 2019 · Journal of Oncology Practice
84. Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
    Zhen Zhang, Xinfeng Chen, Yonggui Tian, Feng Li, Xuan Zhao, Jinyan Liu, Chang Yao, Yi Zhang · 2020 · Journal for ImmunoTherapy of Cancer
85. Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia
    Frank M. Cichocki, Jodie P. Goodridge, Ryan Bjordahl, Sajid Mahmood, Zachary Davis, Svetlana Gaidarova, Ramzey Abujarour, Brian C. Groff, Alec D. Witty, Hongbo Wang et al. · 2022 · Blood
86. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities
    Rajshekhar Chakraborty, Surbhi Sidana, Gunjan L. Shah, Michael Scordo, Betty K. Hamilton, Navneet S. Majhail · 2018 · Transplantation and Cellular Therapy
87. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy
    Il Minn, Steven P. Rowe, Martin G. Pomper · 2019 · The Lancet Oncology
88. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
    Cheng Zhang, Xiaoqi Wang, Rongli Zhang, Fang Liu, Yi Wang, Zhiling Yan, Yongping Song, Ting Yang, Ping Li, Zhen Wang et al. · 2020 · Leukemia
89. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
    Norihiro Watanabe, Mary Kathryn McKenna, Amanda Rosewell Shaw, Masataka Suzuki · 2020 · Molecular Therapy
90. Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
    Richard J. Burt, Dana Warcel, Adele Kay Fielding · 2018 · Human Vaccines & Immunotherapeutics
91. Recent Advances in Managing Acute Lymphoblastic Leukemia
    Daniel J. DeAngelo, Elias Joseph Jabbour, Anjali S. Advani · 2020 · American Society of Clinical Oncology Educational Book
92. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
    Yuru Nie, Weiqing Lu, Daiyu Chen, Huilin Tu, Zhenling Guo, Xuan Zhou, Meifang Li, Sanfang Tu, Yuhua Li · 2020 · Biomarker Research
93. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy
    Victor E. Tedesco, Chandra Mohan · 2021 · The Journal of Immunology
94. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
    Nikhil Hebbar, Rebecca Epperly, Abishek Balachandra Vaidya, Unmesha Thanekar, Sarah E. Moore, Masayuki Umeda, Jing Ma, Sagar L. Patil, Deanna M. Langfitt, Sujuan Huang et al. · 2022 · Nature Communications
95. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis
    Hui Zhang, Chaoke Bu, Zhiyong Peng, Guangchao Li, Zhao Zhou, Wen Yuan Ding, Yongwei Zheng, Yingyi He, Zhengbin Hu, Kunlin Pei et al. · 2022 · Leukemia
96. Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
    MyLinh T. Duong, Matthew R. Collinson-Pautz, Éva Morschl, An Lu, Sławomir Szymański, Ming Zhang, Mary E. Brandt, Wei-Chun Chang, Kelly L. Sharp, Steven M. Toler et al. · 2018 · Molecular Therapy — Oncolytics
97. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
    Bhagirathbhai Dholaria, Christina A. Bachmeier, Frederick Lundry Locke · 2018 · BioDrugs
98. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
    Jay Alan Fishman, John I Hogan, Marcela Valderrama Maus · 2018 · Clinical Infectious Diseases
99. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer
    Cristina Gutiérrez, Colleen A. McEvoy, Laveena Munshi, Robert Scott Stephens, Michael E. Detsky, Joseph L. Nates, Stephen M. Pastores · 2019 · Critical Care Medicine
100. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
     Rawan G. Faramand, Michael David Jain, Verena Staedtke, Hiroshi Kotani, Ren-Yuan Bai, Kayla M. Reid, Sae Bom Lee, Kristen Spitler, Xuefeng Wang, Biwei Cao et al. · 2020 · Clinical Cancer Research